<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1561-3194</journal-id>
<journal-title><![CDATA[Revista de Ciencias Médicas de Pinar del Río]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Ciencias Médicas]]></abbrev-journal-title>
<issn>1561-3194</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1561-31942021000500013</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Selección de blanco terapéutico en la catepsina B para el desarrollo de fármacos contra el cáncer de mama]]></article-title>
<article-title xml:lang="en"><![CDATA[Therapeutic targeting of Cathepsin B for the development of drugs for breast cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[de Dios Hernández]]></surname>
<given-names><![CDATA[Daneilys]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Pinar del Río Facultad de Ciencias Médicas &#8220;Dr. Ernesto Che Guevara de la Serna&#8221; ]]></institution>
<addr-line><![CDATA[Pinar del Río ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2021</year>
</pub-date>
<volume>25</volume>
<numero>5</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1561-31942021000500013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1561-31942021000500013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1561-31942021000500013&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: el cáncer de mama se ha incrementado en un 50 % en las dos últimas décadas. La catepsina B es una proteasa que participa en el proceso de tumurogénesis. Uno de los problemas actuales es la aparición de resistencias a fármacos. La búsqueda de nuevas alternativas terapéuticas puede reducir su morbimortalidad.  Objetivo: caracterizar in silico estructural y funcionalmente la región conservada en la catepsina B como blanco terapéutico potencial en el tratamiento del cáncer de mama  Métodos: con el uso de la herramienta ENTREZ del NCBI se obtuvieron 2 485 secuencias de la catepsina B. Las secuencias son sometidas a un alineamiento múltiple empleando Clustall Omega 1.2.4. Se realiza la caracterización estructural y funcional de la proteasa en estudio a partir de las bases de datos InterPro, Prosite, Uniprot y UniprotKB. Con el empleo del visualizador Jalview se seleccionó la mayor zona conservada de las especies de catepsina B.  Resultados: la proteasa participa en la regulación de la actividad catalítica, proteólisis, regulación negativa de la muerte celular, procesos catabólicos del colágeno y posee actividad hidrolasa. El análisis múltiple permitió la visualización de las características aminoacídicas del sitio activo de la catepsina B y la selección de la región proteica más conservada.  Conclusiones: la zona conservada de la catepsina B constituye un blanco potencial en el desarrollo de inhibidores como fármacos contra el cáncer de mama. Los análisis in silico reducen costo de las investigaciones actuales y contribuyen a la bioseguridad farmacológica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: breast cancer has increased by 50% in the last two decades. Cathepsin B is a protease involved in the process of tumorigenesis. One of the current problems is the emergence of drug resistance. The search for new therapeutic alternatives can reduce its morbidity and mortality.  Objective: in-silico structural and functional characterization of the conserved region in Cathepsin B as a potential therapeutic target in the treatment of breast cancer.  Methods:  using the NCBI ENTREZ tool 2,485 Cathepsin B sequences were obtained. The sequences were subjected to multiple alignments using Clustall Omega 1.2.4. Structural and functional characterization of the protease under study was performed using the InterPro, Prosite, Uniprot and UniprotKB databases. Using the Jalview viewer, the largest conserved area of Cathepsin B species was chosen.  Results:  the protease is involved in the regulation of catalytic activity, proteolysis, negative regulation of cell death, collagen catabolic processes and possesses hydrolase activity. The multiple analyses allowed the visualization of the aminoacid characteristics of the active site of Cathepsin B and the selection of the most conserved protein region.  Conclusions:  the conserved region of Cathepsin B constitutes a potential target in the development of inhibitors as drugs against breast cancer. In-silico analysis reduces the cost of current research and contributes to pharmacological biosafety.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[NEOPLASIAS DE LA MAMA]]></kwd>
<kwd lng="es"><![CDATA[CATEPSINA B]]></kwd>
<kwd lng="es"><![CDATA[INHIBIDORES]]></kwd>
<kwd lng="es"><![CDATA[MORBIMORTALIDAD]]></kwd>
<kwd lng="en"><![CDATA[BREAST NEOPLASMS]]></kwd>
<kwd lng="en"><![CDATA[CATHEPSIN B]]></kwd>
<kwd lng="en"><![CDATA[INHIBITORS]]></kwd>
<kwd lng="en"><![CDATA[MORBIDITY AND MORTALITY]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waks]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Winer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer treatment a review]]></article-title>
<source><![CDATA[Rev Clinical Review and Education]]></source>
<year>2019</year>
<volume>321</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Piñeros]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patrones, tendencias y proyecciones del cáncer en América Latina y el Caribe: un contexto global]]></article-title>
<source><![CDATA[Salud Pública Mex]]></source>
<year>2016</year>
<volume>58</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez Valle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García Montesino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lores Hechevarria]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Azcuy]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez Hernández]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Histología e inmunohistoquímica del cáncer de mama invasivo en la provincia de Pinar del Río]]></article-title>
<source><![CDATA[Rev. cienc. méd. Pinar Río]]></source>
<year>2019</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>71-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Anuario estadístico 2018]]></source>
<year>2019</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jaeger]]></surname>
<given-names><![CDATA[Samira]]></given-names>
</name>
<name>
<surname><![CDATA[Igea]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<name>
<surname><![CDATA[Arroyo]]></surname>
<given-names><![CDATA[Rodrigo]]></given-names>
</name>
<name>
<surname><![CDATA[Alcalde]]></surname>
<given-names><![CDATA[Victor]]></given-names>
</name>
<name>
<surname><![CDATA[Canovas]]></surname>
<given-names><![CDATA[Begoña]]></given-names>
</name>
<name>
<surname><![CDATA[Orozco]]></surname>
<given-names><![CDATA[Modesto]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quantification of pathway crosstalk reveals novel synergistic drug combinations for breast cancer]]></article-title>
<source><![CDATA[Rev Cancer Research]]></source>
<year>2017</year>
<volume>77</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>459-69</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aggarwal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sloane]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cathepsin B: Multiple roles in cancer]]></article-title>
<source><![CDATA[Rev Proteomics Clin. Appl]]></source>
<year>2014</year>
<volume>8</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>427-37</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gondi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cathepsin B as a cancer target]]></article-title>
<source><![CDATA[Rev Expert Opin Ther Targets]]></source>
<year>2013</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>281-91</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naranjo Feliciano]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis in silico de la catepsina B de Fasciola hepática como diana terapéutica]]></article-title>
<source><![CDATA[REDVET]]></source>
<year>2009</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-36</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nelson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cox]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Aminoácidos, péptidos y proteínas. En: Freeman WH, eds. Lehninger Principios de Bioquímica]]></source>
<year>2009</year>
<edition>5ta</edition>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Omega]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cathepsin B and L inhibitors: a patent review (2010 - present)]]></article-title>
<source><![CDATA[Expert Opinion on Therapeutic Patents]]></source>
<year>2017</year>
<volume>27</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>643-56</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Raghav]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibitory potential of some chalcones on cathepsins B, H and L]]></article-title>
<source><![CDATA[RCS Adv]]></source>
<year>2015</year>
<volume>5</volume>
<page-range>72937-49</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Socic]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mitrovic]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Curic]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Knez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Brodnik]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Stefane]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cathepsin B inhibitors: Further exploration of the nitroxoline core]]></article-title>
<source><![CDATA[Bioorganic &amp; Medicinal Chemistry Letters]]></source>
<year>2018</year>
<volume>28</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1239-47</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rational design of a humanized antibody inhibitor of cathepsin B]]></article-title>
<source><![CDATA[Biochemistry]]></source>
<year>2020</year>
<volume>59</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1420-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toupin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Arora]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shrestha]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fischer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rajagurubandara]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[BODIPY-caged photoactivated inhibitors of cathepsin B flip the light switch on cancer cell apoptosis. ACS Chem]]></article-title>
<source><![CDATA[Biol]]></source>
<year>2019</year>
<volume>14</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2833-40</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rajagopal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Arumugasamy]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Byran]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pandiyan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Sustituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer]]></article-title>
<source><![CDATA[International Journal of Computational and Theoretical Chemistry]]></source>
<year>2019</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6-13</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maruthanila]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Elancheran]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nand]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Anupam]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[AjaiKumar]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kabilan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In silico Molecular Modelling of Selected Natural Ligands and their Binding Features with Estrogen Receptor Alpha]]></article-title>
<source><![CDATA[Current Computer]]></source>
<year>2019</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>89-96</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
